Shots:

• The company reported the new results of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine against Omicron sublineages, incl. BA.4.6, BA.2.75.2, BQ.1.1 & XBB.1
• The results showed that the bivalent vaccine booster elicited a greater increase in neutralizing Ab titers over the original COVID-19 vaccine, neutralizing Ab titers against Omicron sublineages BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 increased 4.8 to 11.1 fold from pre-booster levels, following a 30µg booster dose of the bivalent vaccine while 1.5 to 2.3 fold, following a booster dose of COVID-19 vaccine
• The booster dose of the bivalent vaccine has been authorized in the US for emergency use in patients aged ≥5yrs. & received EC’s marketing authorization in the EU

Ref: Pfizer | Image: BioNTech